Pipeline Report: October 2021
October 27th 2021
The ATR inhibitor RP-3500 demonstrated a manageable safety profile and promising early antitumor efficacy in patients whose tumors harbor select genomic alterations when administered at doses of 100 mg or more.
October 26th 2021
The administration of NBTXR3 monotherapy activated by radiotherapy resulted in encouraging survival improvements in difficult-to-treat elderly and frail patients with locally advanced head and neck squamous cell carcinoma who are ineligible for cisplatin and intolerant to cetuximab.